NEW YORK, March 1 NeoStem, Inc. (NYSE: NBS)("NeoStem" or the "Company"), an international biopharmaceutical company withoperations in the United States and China, announced today that it hasappointed to its Scientific Advisory Board ("SAB") Mariusz Ratajczak, M.D.,Ph.D., a world renowned investigator in the field of adult stem cells andco-inventor of the VSEL(TM) technology to which the Company has an exclusivelicense from the University of Louisville Research Foundation ("ULRF").
Dr. Ratajczak is the director of the Stem Cell Institute ("SCI") at theJames Graham Brown Cancer Center at the University of Louisville and aprofessor in the Department of Microbiology and Immunology at the sameuniversity. As a thought leader in the field of adult stem cell biology, hehas published numerous books and more than 300 peer-reviewed publications andis a frequent speaker at conferences worldwide.
Through the pioneering research work led by Dr. Ratajczak, his teamdiscovered a heterogeneous population of stem cells, in the bone marrow, withproperties similar to those of an embryonic stem cell, known as very smallembryonic-like stem cells. This ground breaking discovery opens the door forthe potential application of these special cells to provide positive benefitsassociated with embryonic stem cells without certain of the potential negativeor controversial effects associated with embryonic stem cells. Combined withNeoStem's stem cell banking capabilities to collect, process and store verysmall embryonic-like cells from individual donors, these special cells havesignificant potential for autologous use in the future in a variety ofpersonalized medicine applications.
Prior to joining NeoStem's SAB as a formal advisor, Dr. Ratajczak wasalready collaborating with the Company through a sponsored research agreementconducting further research relating to VSEL(TM) technology and itspotentially vast applications. Dr. Ratajczak's team at the University ofLouisville has published preliminary work that suggests very smallembryonic-like stem cells potentially have a prominent role in regenerativemedicine to repair degenerated, damaged or diseased tissue.
"NeoStem is a leader in pursuing innovative approaches to cell-basedtherapeutics," said Dr. Ratajczak. "I look forward to working with Dr.Marasco and the rest of the Scientific Advisory Board to help the Companyadvance the application of VSEL(TM) technology to fulfill our goal of itsplaying an important role as a new generation of stem cell therapies anddiagnostics."
Wayne A. Marasco, M.D., Ph.D., chair of NeoStem's Scientific AdvisoryBoard, said, "We welcome Dr. Ratajczak's important addition to the Company'sScientific Advisory Board and look forward to further leveraging hissignificant research experience and leadership in the stem cell field. Dr.Ratajczak is an internationally recognized expert in stem cell research, andhis discovery of very small embryonic-like stem cells has provided researcherswith a novel platform from which to accelerate progress in the rapidlyemerging field of regenerative medicine."
In addition to collaborations with Dr. Ratajczak and other researchers,the Company is working on its own to develop adult stem cell therapeutics anddiagnostic tools that leverage the VSEL(TM) technology know-how and isdeveloping other isolation methods for very small embryonic-like stem cellsand establishing a stem cell high-throughput analysis for personalizedscreening.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies,pursuit of anti-aging initiatives and building of a network of adult stem cellcollection centers in the U.S. and China that are focused on enabling peopleto donate and store their own (autologous) stem cells for their personal usein times of future medical need. The Company is also the licensee of variousstem cell technologies, including a worldwide exclusive license to VSEL(TM)technology which uses very small embryonic-like stem cells, shown to haveseveral physical characteristics that are generally found in embryonic stemcells, and is pursuing the licensing of other technologies for therapeutic use.NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye,manufactures and distributes generic antibiotics in China. For moreinformation, please visit: http://www.neostem.com .
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Forward-lookingstatements reflect management's current expectations, as of the date of thispress release, and involve certain risks and uncertainties. Forward lookingstatements include statements herein with respect to the application ofVSEL(TM) technology and success of developing stem cell therapeutics anddiagnostics for regenerative diseases, about which no assurances can be given.The Company's actual results could differ materially from those anticipated inthese forward-looking statements as a result of various factors. Factors thatcould cause future results to materially differ from the recent results orthose projected in forward-looking statements include the "Risk Factors"described in the Company's Registration Statement on Form S-1 filed with theSecurities and Exchange Commission on as well as periodic filings made withthe Securities and Exchange Commission. The Company's further development ishighly dependent on future medical and research developments and marketacceptance, which is outside its control.For more information, please contact: NeoStem, Inc. Robin Smith, CEO Phone: +1-212-584-4174 Email: email@example.com Web: http://www.neostem.com CCG Investor Relations, Inc. Lei Huang, Account Manager Phone: +1-646-833-3417 Email: firstname.lastname@example.org Web: http://www.ccgirasia.com Crocker Coulson, President Phone: +1-646-213-1915 Email: email@example.com
SOURCE NeoStem, Inc.